Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Overview | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Stage of Development | 10 | 1 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Therapy Area | 11 | 1 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Indication | 12 | 2 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Unknown Stage Products | 16 | 1 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Companies | 17 | 4 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Products under Development by Universities/Institutes | 21 | 2 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Therapeutics Assessment | 23 | 6 |
| Assessment by Monotherapy/Combination Products | 23 | 1 |
| Assessment by Mechanism of Action | 24 | 1 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Companies Involved in Therapeutics Development | 29 | 11 |
| Akari Therapeutics, Plc | 29 | 1 |
| Alexion Pharmaceuticals, Inc. | 30 | 1 |
| Alnylam Pharmaceuticals, Inc. | 31 | 1 |
| Amgen Inc. | 32 | 1 |
| Epirus Biopharmaceuticals, Inc. | 33 | 1 |
| InflaRx GmbH | 34 | 1 |
| Novartis AG | 35 | 1 |
| Noxxon Pharma AG | 36 | 1 |
| Ophthotech Corp. | 37 | 1 |
| Ra Pharmaceuticals, Inc. | 38 | 1 |
| Swedish Orphan Biovitrum AB | 39 | 1 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Drug Profiles | 40 | 41 |
| AcPepA Drug Profile | 40 | 1 |
| ALN-CC5 Drug Profile | 41 | 4 |
| ALXN-1007 Drug Profile | 45 | 1 |
| ALXN-1210 Drug Profile | 46 | 1 |
| ALXN-5500 Drug Profile | 47 | 1 |
| avacincaptad pegol sodium Drug Profile | 48 | 2 |
| Bikaciomab Drug Profile | 50 | 1 |
| BikajuMab Drug Profile | 51 | 1 |
| Coversin Drug Profile | 52 | 3 |
| eculizumab Drug Profile | 55 | 10 |
| eculizumab biosimilar Drug Profile | 65 | 1 |
| eculizumab biosimilar Drug Profile | 66 | 1 |
| IFX-1 Drug Profile | 67 | 2 |
| IFX-2 Drug Profile | 69 | 1 |
| Monoclonal Antibody for Ischemia Reperfusion Injury Drug Profile | 70 | 1 |
| NM-9405 Drug Profile | 71 | 1 |
| NOXD-21 Drug Profile | 72 | 1 |
| Protein to Inhibit Complement C5 for Immunology Drug Profile | 73 | 1 |
| RA-101295 Drug Profile | 74 | 1 |
| RA-101348 Drug Profile | 75 | 1 |
| RA-101495 Drug Profile | 76 | 1 |
| SOBI-005 Drug Profile | 77 | 1 |
| Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation Drug Profile | 78 | 1 |
| tesidolumab Drug Profile | 79 | 2 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Dormant Projects | 81 | 2 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Discontinued Products | 83 | 1 |
| Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Featured News &Press Releases | 84 | 11 |
| Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery | 84 | 1 |
| Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) | 84 | 2 |
| Jun 03, 2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data | 86 | 1 |
| Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | 86 | 1 |
| May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barr Syndrome | 87 | 1 |
| May 19, 2016: Researchers to Present Additional Data, Including Late-Breaking Results on ALXN1007 in Patients with GI-GVHD at EHA Annual Congress | 87 | 1 |
| May 19, 2016: Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated | 88 | 1 |
| May 19, 2016: Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress | 89 | 1 |
| May 19, 2016: Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association | 89 | 1 |
| May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barr Syndrome | 90 | 1 |
| May 09, 2016: EPIRUS Announces Reprioritization of Pipeline, to focus on biosimilar product BOW080 | 91 | 1 |
| Mar 31, 2016: Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin | 91 | 1 |
| Feb 16, 2016: A Statement from the Executive Officer of the Ontario Public Drug Programs on behalf of the pCPA | 92 | 1 |
| Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines &Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial | 93 | 1 |
| Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody | 93 | 2 |
| Appendix | 95 | 2 |
| Methodology | 95 | 1 |
| Coverage | 95 | 1 |
| Secondary Research | 95 | 1 |
| Primary Research | 95 | 1 |
| Expert Panel Validation | 95 | 1 |
| Contact Us | 95 | 1 |
| Disclaimer | 96 | 1 |